FOR IMMEDIATE DISTRIBUTION

JEFFERIES ENHANCES EQUITY RESEARCH PLATFORM
WITH ADDITION OF SENIOR BIOTECHNOLOGY ANALYST

NEW YORK, April 22 2010 -- In an expansion of the firm's established healthcare research franchise, Jefferies announced today the addition of Andrew Fein as a Managing Director and Senior Equity Research Analyst covering Biotechnology companies. Mr. Fein has more than ten years of experience as an analyst following the Biotechnology industry.

The hiring of Mr. Fein extends Jefferies' established coverage of Biotechnology, which includes senior analysts Thomas Wei and Eun Yang, Ph.D. in the US, and Peter Welford, CFA, Philippa Gardner, Eng.D. Tara Shivarattan, Ph.D. and James Vane-Tempest in Europe. Jefferies' Healthcare research team, one of the largest in the world, is comprised of 20 analysts globally, covering Biotechnology, Pharmaceuticals, Specialty Pharmaceuticals, Contract Research Organizations (CROs), Medical Devices, Medical Diagnostics, Life Sciences Tools, Healthcare Supplies, Healthcare Information Technology, Medical Technology, as well as Healthcare Services, Facilities and REITs.

"Andrew Fein is a highly-regarded research analyst with strong relationships and a successful track record of covering Biotechnology companies," commented Steven R. Black, Global Head of Equity Research at Jefferies. "His experience and sector expertise will further extend our existing Healthcare research franchise and add immediate value to our comprehensive equity offering to institutional investors."

Jefferies' research analysts consistently rank among the top industry professionals, capturing 23 analyst awards in 2009, including honors from The Wall Street Journal "Best on the Street" Analyst Survey, Institutional Investor and Financial Times/StarMine. Jefferies and its affiliates have nearly 175 equity and leveraged finance research professionals in the US and Europe covering over 1,300 companies in the areas of aerospace & defense, clean technology, consumer, energy, financial services, gaming & leisure, healthcare, industrials, maritime, media & entertainment, technology, telecommunications and utilities.

Mr. Fein was most recently at Piper Jaffray, where he was a Managing Director covering Biotechnology companies. Previously, he was a Managing Director covering Biotechnology companies at Collins Stewart (formerly C.E. Unterberg, Towbin) and held similar roles at Leerink Swann, J.P. Morgan and Deutsche Bank. He received a BA in Biology and History from Yale University.

Jefferies, a major global securities and investment banking firm, has served companies and their investors for more than 45 years. Jefferies & Company, Inc. is the principal operating subsidiary of Jefferies Group, Inc. (NYSE: JEF: jefferies.com).

For further information, please contact:

Tom Tarrant, Jefferies & Company, Inc., 203 708 5989, ttarrant@jefferies.com
Desiree Maghoo, Jefferies International Ltd, 44 20 7029 8085, dmaghoo@jefferies.com
Josh Passman, CJP Communications, 212 279 3115, x203, jpassman@cjpcom.com